Amgen (NASDAQ:AMGN) and collaboration partner Allergan (NYSE:AGN) announce positive results from a second Phase 3 clinical trial, JASMINE, evaluating biosimilar candidate ABP 798 to the branded product, Roche’s (OTCQX:RHHBY) Rituxan (rituximab) in patients with CD20-positive B-cell non-Hodgkin lymphoma. The data showed clinical equivalence as well as comparable safety and immunogenicity.
The first Phase 3 demonstrated pharmacokinetic similarity in patients with moderate-to-severe rheumatoid arthritis.
The companies are co-developing and co-commercializing four oncology biosimilars under a 2011 agreement.
Development is ongoing.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.